How Has the Xerostomia Therapeutics Market Size Evolved in Recent Years?
The xerostomia therapeutics market has seen considerable growth due to a variety of factors.
• The xerostomia therapeutics market has shown steady growth in recent years. It will rise from $2.14 billion in 2024 to $2.26 billion in 2025, at a CAGR of 5.7%.
This growth is attributed to the rising incidences of xerostomia among the elderly, research and development of better therapeutic products, greater awareness of xerostomia-related products, increasing medical conditions, and the rising prevalence of chronic diseases.
What Is The Forecast For The Xerostomia Therapeutics Market Size?
The xerostomia therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The xerostomia therapeutics market is anticipated to grow steadily, reaching $2.79 billion by 2029 at a CAGR of 5.3%.
Growth is driven by the availability of affordable medications, the rise in oral health conditions, increased awareness among healthcare professionals, government initiatives, and rising medication use. Trends include artificial saliva and saliva substitutes, product innovations, personalized medicine, telehealth integration, and the rise of non-invasive treatments.
What Are The Essential Drivers Behind The Growth Of The Xerostomia Therapeutics Market?
The growth of the xerostomia therapeutics market is anticipated to be driven by the escalating use of chemotherapy in cancer treatments. The application of strong medicines to reduce or destroy cancer cells defines chemotherapy in cancer treatment. The popularization of chemotherapy stems mainly from its efficiency in particularly targeting and eliminating malign cells in the body. Treatments for xerostomia involve medications that stimulate saliva or mouth washes that augment saliva production and improve taste sensation, facilitating easier eating and ensuring sufficient nutrition for patients. For example, the National Cancer Institute, a US government agency, reported in January 2022 that the country had approximately 18.1 million cancer survivors, comprising 5.4% of the overall population. By 2032, it is projected that the global number of cancer survivors will reach 22.5 million, marking a 24.4% growth from the present figure. Consequently, the widespread use of chemotherapy in cancer treatments is fuelling the expansion of the xerostomia therapeutics market.
How Is The Global Xerostomia Therapeutics Market Divided Into Key Segments?
The xerostomia therapeutics market covered in this report is segmented –
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric
Subsegments:
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges
Pre-Book The Xerostomia Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Xerostomia Therapeutics Market?
Leading firms in the xerostomia therapeutics market are innovating patient-centric, non-invasive treatment methods like oral sprays, in response to the need for convenient and effective dry mouth management solutions. Oral sprays offer accurate delivery to the impacted regions in the mouth, ensuring effective hydration and lubrication exactly where required. For example, in July 2023, K Pharmaceuticals, a pharmaceutical organization based in India, introduced Aquoral, a clinically approved oral spray crafted to alleviate dry mouth symptoms, also referred to as xerostomia. This condition can be triggered by a range of factors such as medications and illnesses and can result in discomfort, problems with chewing and swallowing, and issues related to oral health. Aquoral provides long-standing relief for up to six hours by creating a durable protective layer in the oral cavity, minimizing moisture loss and increasing comfort. In contrast to traditional water-based treatments needing regular reapplication, Aquoral leverages patented Oxidized Glycerol Triesters (OGT), a plant-sourced, lipid-based technology that provides premium protection.
Who Are the Key Players In The Xerostomia Therapeutics Market?
Major companies operating in the xerostomia therapeutics market are:
• Bayer AG
• 3M Company
• GlaxoSmithKline plc
• Colgate-Palmolive Company
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Church & Dwight Co. Inc.
• Cipla Ltd.
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Synedgen Inc.
• Sunstar Suisse S.A.
• Advanz Pharma Corp.
• Pharmascience Inc.
• Mission Pharmacal Company
• Dentaid Ltd.
• Cyclacel Pharmaceuticals Inc.
• Parnell Pharmaceuticals Holdings Ltd.
• Teva Pharmaceutical Industries Ltd.
• Forward Science Holding Inc.
• ICPA Health Products Ltd.
• CCMed Ltd.
• Bio Cosmetics Laboratories S.L.
• Quest Products LLC
• Acacia Pharma
• Saliwell Limited
• OraCoat
• Oralieve UK Ltd.
• OraPharma Inc.
• OraVital Inc
What Are The Regional Insights Into The Xerostomia Therapeutics Market?
North America was the largest region in the xerostomia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
